Abstract'See what you treat and treat what you see, at a molecular level', could be the motto
of theranostics. The concept implies diagnosis (imaging) and treatment of cells (usually …

Bone metastasis develops in multiple malignancies with a wide range of incidence. The
presence of multiple bone metastases, leading to a multitude of complications and poorer …

Simple Summary In this review, we present knowledge of the molecular mechanisms and
therapeutic strategies of bone metastasis of breast cancer, particularly the interaction …

Cancer is one of the leading causes of death in humans. Despite the progress in cancer
treatment, and an increase in the effectiveness of diagnostic methods, cancer is still highly …

Background The alpha-emitter radium-223 (223Ra) is presently used in nuclear medicine
for the palliative treatment of bone metastases from castration-resistant prostate cancer. This …

Simple Summary Human epidermal growth factor receptor 2 (HER2) is a protein present in
increased amounts in breast cancer compared with healthy breast tissue. Anti-cancer drugs …

Radiopharmaceuticals are of growing interests in the development of theranostic agents and
personalized medicine because of their unique advantages. Diagnosis (via molecular …

Purpose This is the first prospective trial evaluating the efficacy of alpha emitter Radium-223
in patients with bone metastases from radioactive iodine (RAI) refractory (RAIR) …

Background Most women with advanced breast cancer have skeletal metastases. Radium-
223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases …

Bone metastases occur frequently in common malignancies such as breast and prostate
cancer. They are responsible for considerable morbidity and skeletal-related events …